Stem Cell Therapy Arbitration —  

Stem cell therapy arbitration refers to the use of arbitration to resolve disputes arising from stem-cell treatment, regenerative medicine, cell-processing agreements, cord-blood/stem-cell banking, clinical research, licensing, biotechnology collaborations, and related healthcare services.

It is a particularly sensitive area because the dispute may involve medical negligence, informed consent, experimental treatment, regulatory approval, patient safety, intellectual property, confidentiality, payment obligations, and scientific evidence simultaneously.

A major distinction should be kept in mind: not every dispute involving stem-cell treatment is arbitrable. A purely commercial dispute between a biotechnology company and a hospital may readily be arbitrated, while regulatory questions concerning whether an unapproved therapy may legally be administered may fall within public-law or statutory jurisdiction.

1. Meaning of Stem Cell Therapy Arbitration

Stem-cell therapy involves the use of stem cells or cellular products for therapeutic or regenerative purposes. Contractual relationships may exist among:

patient and hospital;

patient and stem-cell clinic;

patient and cord-blood bank;

hospital and biotechnology company;

biotechnology company and pharmaceutical company;

researcher and sponsoring institution;

cell-processing laboratory and hospital;

technology licensor and cell-therapy developer;

manufacturer and distributor of cellular products;

international research collaborators.

If the underlying agreement contains an arbitration clause, contractual disputes may be referred to arbitration.

Typical disputes include:

failure to provide promised treatment;

failure of stored stem cells to remain viable;

loss or destruction of biological material;

incorrect collection or processing;

breach of clinical-trial obligations;

failure to obtain regulatory approvals;

unauthorized advertising of therapeutic benefits;

breach of confidentiality;

misuse of genetic or biological information;

non-payment of research or licensing fees;

intellectual-property disputes;

breach of representations concerning efficacy or safety;

disputes concerning clinical outcomes;

termination of biotechnology collaborations.

2. Why Arbitration Is Important in Stem Cell Disputes

Stem-cell disputes frequently contain confidential scientific and commercial information.

Arbitration can provide:

A. Confidentiality

The parties may wish to protect:

patient information;

genetic information;

clinical trial data;

proprietary cell-processing methods;

laboratory protocols;

research results;

patent information;

commercial agreements.

B. Scientific Expertise

An arbitral tribunal can include arbitrators with experience in:

biotechnology;

pharmaceutical law;

medical technology;

intellectual property;

clinical trials.

C. Cross-Border Enforcement

Stem-cell research and biotechnology are increasingly international. A company in India may collaborate with a laboratory in Singapore, China, the United States, or Europe.

An arbitration agreement can provide a neutral forum, while a resulting foreign award may potentially be enforced under the New York Convention, subject to applicable law and public-policy limitations.

D. Flexible Evidence

Stem-cell disputes may require:

laboratory records;

genetic testing;

medical records;

chain-of-custody documentation;

clinical-trial data;

expert reports;

scientific literature;

regulatory correspondence.

Arbitration can provide procedural flexibility for such evidence.

3. The Most Important Legal Issue: Arbitrability

The first question is not simply whether an arbitration clause exists.

The tribunal or court must determine:

Is this particular dispute legally capable of being decided by arbitration?

A useful distinction is:

Thus, an arbitration clause cannot transform a regulatory question into a private commercial dispute.

4. Indian Regulatory Background

Stem-cell arbitration in India must be understood against the regulatory framework governing stem-cell research and therapy.

The National Guidelines for Stem Cell Research, 2017, together with the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, medical-professional regulation and other applicable laws, are highly relevant.

The Supreme Court's 2026 decision in Yash Charitable Trust v. Union of India is particularly important because it directly examined the legal position surrounding stem-cell therapy for autism and the distinction between legitimate research and administration of unproven therapy. (Indian Kanoon)

This means that an arbitration tribunal dealing with a stem-cell contract cannot simply disregard mandatory Indian regulatory requirements.

5. Important Case Laws

There are relatively few reported arbitral awards specifically concerning stem-cell therapy because many biotechnology and medical arbitrations remain confidential. Therefore, the most useful authorities include direct stem-cell arbitration decisions, cord-blood/stem-cell disputes, and closely connected biotechnology cases.

Case 1 — Tenet Healthcare Corp. v. Maharaj

Tenet Healthcare Corp. v. Maharaj, 787 So. 2d 241 (Fla. Dist. Ct. App. 2001)

Facts

The dispute concerned the Bone Marrow/Stem Cell Transplant Institute of Florida. Dr. Dipnarine Maharaj had served as Medical Director, while his corporation, Stem Cell, Inc., had founded the institute.

Following termination of his position, litigation arose concerning contractual and partnership rights.

The relevant agreements contained arbitration clauses.

Issue

Whether the contractual dispute should be stayed and referred to arbitration.

Decision

The appellate court reversed the refusal to compel arbitration.

Principle

Where parties have entered into agreements containing sufficiently broad arbitration provisions, contractual disputes arising from the relationship should generally be submitted to arbitration.

The agreements also contemplated court intervention for certain urgent equitable relief.

Importance

This is one of the most directly relevant reported cases because the underlying institution was specifically a bone-marrow/stem-cell transplant institute.

It demonstrates that disputes concerning:

management of a stem-cell institution;

physician relationships;

ownership;

contractual termination;

partnership rights

can fall within arbitration. (FindLaw)

6. Cohen v. CBR Systems, Inc.

Cohen v. CBR Systems, Inc., No. 21-cv-06527-HSG (N.D. Cal. 2022)

Facts

CBR Systems provided newborn stem-cell processing and preservation services through private cord-blood banking.

Customers alleged that CBR increased storage charges and engaged in deceptive marketing and billing practices.

The contracts contained arbitration provisions.

Issue

Could CBR compel arbitration?

Decision

The federal district court granted the motions to compel arbitration.

The court examined the arbitration provisions and the parties' contractual relationship and found that arbitration was required. (GovInfo)

Importance

This is highly relevant to consumer-facing stem-cell banking contracts.

It illustrates that an arbitration clause in a cord-blood/stem-cell preservation agreement can govern disputes concerning:

storage charges;

contractual representations;

billing;

deceptive practices;

service obligations.

The case also demonstrates the importance of making arbitration provisions sufficiently visible and procedurally workable.

7. Polesuk v. CBR Systems, Inc.

Polesuk v. CBR Systems, Inc., No. 05-CV-8324 (S.D.N.Y. 2006)

Facts

Cord blood intended for cryogenic preservation by CBR was allegedly destroyed while being transported to the facility.

The cord blood was intended for possible future use in stem-cell therapy.

CBR's contractual relationship with the customer and its cross-claims against the courier raised arbitration and transportation-liability issues.

Significance

The case demonstrates that stem-cell disputes may extend beyond the actual medical procedure.

The legally significant chain may be:

collection → transportation → laboratory receipt → processing → cryopreservation → storage → retrieval → transplantation.

Failure at any stage can generate contractual liability.

The court noted that CBR's cross-claims against the courier were stayed pending arbitration. (Casemine)

Arbitration Lesson

A stem-cell agreement should therefore expressly allocate responsibility for:

collection;

packaging;

transportation;

temperature control;

chain of custody;

laboratory receipt;

storage;

retrieval.

8. Westenfelder v. Novo Ventures

Westenfelder v. Novo Ventures (US), Inc., 797 F. Supp. 2d 188 (D. Mass. 2011)

Facts

The plaintiffs were physicians involved in developing stem-cell-related treatments for acute kidney injury.

They had formed Nephrogen to pursue research and commercial exploitation of their inventions.

Consulting agreements contained arbitration provisions.

A later dispute concerned rights under a separate Stock Restriction Agreement.

Issue

Did the arbitration clause in the consulting agreements cover the later dispute?

Decision

The court held that the particular claim was not within the scope of the arbitration clause and enjoined arbitration of that claim. (MidPage)

Principle

An arbitration clause does not automatically cover every dispute between parties simply because the parties have a broader commercial relationship.

The tribunal must examine:

wording of the arbitration clause;

agreement in which it appears;

nature of the particular claim;

relationship between the disputed obligation and the contract containing the clause.

Importance

This is extremely important in stem-cell research contracts.

A biotechnology collaboration may contain several documents:

research agreement;

investment agreement;

employment agreement;

IP assignment;

licensing agreement;

clinical-trial agreement.

Each should clearly state whether its arbitration clause covers disputes under the other related agreements.

9. Cesca Therapeutics Inc. v. SynGen, Inc.

Cesca Therapeutics Inc. v. SynGen, Inc., No. 2:14-cv-02085 (E.D. Cal. 2015)

Facts

Cesca Therapeutics developed and commercialized medical products associated with cryopreservation of stem cells and cellular tissues used in regenerative medicine.

The defendants attempted to compel arbitration.

Issue

Whether the contractual arrangements contained an applicable arbitration agreement covering the claims.

Decision

The court denied the motion to compel arbitration because the defendants failed to establish a controlling arbitration provision applicable to the action. (Justia Dockets & Filings)

Importance

The case demonstrates a basic but critical principle:

A party cannot rely upon arbitration merely because the dispute arises within the biotechnology sector; an applicable arbitration agreement must actually exist.

For stem-cell technology companies, contracts should therefore clearly identify:

parties;

covered agreements;

incorporated documents;

disputes covered;

arbitration institution;

seat;

governing law.

10. CASI Pharmaceuticals Inc. v. Juventas Cell Therapy Ltd.

CASI Pharmaceuticals Inc. v. Juventas Cell Therapy Ltd. — HKIAC arbitration

This is a particularly important international biotechnology arbitration.

Parties

The dispute involved:

CASI Pharmaceuticals, a Cayman Islands company; and

Juventas Cell Therapy Ltd., a Chinese biotechnology company.

Nature of dispute

The case concerned a commercial dispute within the pharmaceutical and biotechnology/cell-therapy sector.

The arbitration was conducted under the HKIAC Administered Arbitration Rules.

Proceedings

The matter involved:

emergency relief;

interim relief;

international arbitration;

biotechnology/cell-therapy commercial rights.

The recorded proceedings indicate emergency relief in April 2024, interim relief in February 2025, and a final award in July 2026. (Jus Mundi)

Importance

This is particularly useful for understanding how international cell-therapy disputes can be handled through institutional arbitration.

It demonstrates the importance of emergency/interim relief where the disputed subject matter may involve:

valuable biological technology;

clinical development rights;

licensing rights;

intellectual property;

regulatory approvals;

rapidly changing commercial circumstances.

Because the detailed award is not publicly available, its procedural existence should not be treated as establishing a substantive rule on liability.

11. Sharanya Sinha v. LifeCell International Pvt. Ltd.

Sharanya Sinha v. LifeCell International Pvt. Ltd. (Delhi consumer proceedings, 2024)

Although this was not an arbitration award, it is highly relevant to contractual disputes involving stem-cell banking.

Facts

The consumer purchased a service for:

collection;

processing;

testing;

preservation

of umbilical cord blood stem cells.

After collection, the cord blood was reportedly misplaced during transit.

The customer sought substantial compensation.

Decision

The consumer forum found deficiency in service and awarded ₹20 lakh compensation.

The decision emphasized that once the stem-cell bank undertakes to collect the biological material, responsibility cannot simply be avoided by treating transportation as someone else's problem. (Indian Kanoon)

Arbitration Relevance

The case demonstrates the importance of contractual provisions dealing with:

custody;

transportation;

loss;

sample viability;

substitute stem cells;

compensation;

liability caps.

A comparable dispute between commercial parties could potentially be presented to an arbitral tribunal if the contract contained a valid arbitration clause.

12. Yash Charitable Trust v. Union of India

Yash Charitable Trust v. Union of India, 2026 INSC 96

This is perhaps the most important Indian regulatory case for modern stem-cell disputes.

Background

The case concerned the use and promotion of stem-cell therapy for Autism Spectrum Disorder (ASD).

The petition raised questions concerning:

experimental stem-cell treatment;

National Guidelines for Stem Cell Research;

New Drugs and Clinical Trials Rules, 2019;

professional responsibility;

patient consent;

regulation of clinics offering stem-cell treatment.

The Supreme Court examined whether offering unproven stem-cell therapy could satisfy legal and medical standards merely because patients voluntarily agreed to receive it. (Indian Kanoon)

Principle

A patient's willingness to undergo a procedure does not necessarily cure regulatory or professional deficiencies.

In particular, informed consent requires adequate information. A patient cannot meaningfully consent to an intervention if its experimental or unproven character is inadequately disclosed.

Arbitration Importance

Suppose a patient signs:

"I accept all risks and waive all claims against the clinic."

That clause cannot necessarily eliminate mandatory regulatory obligations.

An arbitral tribunal must distinguish:

contractual assumption of risk

from

waiver of mandatory statutory duties.

This distinction is crucial in stem-cell arbitration.

13. Stemcyte India Therapeutics Pvt. Ltd. v. Commissioner of Central Excise & Service Tax

Stemcyte India Therapeutics Pvt. Ltd. v. Commissioner of Central Excise & Service Tax, 2025 INSC 841

The Supreme Court considered the character of services relating to stem-cell storage and supply in the context of the tax treatment of healthcare services.

The case involved arguments concerning whether stem cells stored and supplied for treatment of serious illnesses fell within the relevant healthcare-services exemption. (Indian Kanoon)

Arbitration relevance

Although this was not an arbitration case, it is useful for understanding how courts characterize stem-cell-related services.

In a contractual arbitration, the classification of the service may affect:

tax;

contractual price;

reimbursement;

regulatory compliance;

allocation of statutory costs.

14. Major Issues in Stem Cell Therapy Arbitration

A. Informed Consent

This is one of the most difficult issues.

The arbitration clause cannot be treated as a substitute for informed consent.

A proper agreement should disclose:

experimental status;

known risks;

unknown risks;

expected benefits;

alternative treatments;

probability of success;

possibility of failure;

possibility of adverse effects.

The Yash Charitable Trust decision makes this especially significant in India. (Indian Kanoon)

B. Experimental vs Approved Therapy

A central dispute may be:

Was the stem-cell procedure an approved treatment or an experimental intervention?

This can affect:

legality;

informed consent;

professional negligence;

advertising;

compensation;

insurance;

regulatory liability.

An arbitration tribunal should not assume that contractual language alone determines regulatory status.

15. Failure of Stem Cells to Remain Viable

A contract may promise:

"The stored stem-cell sample will remain available for future therapeutic use."

A dispute could arise if:

cells lose viability;

storage temperature fails;

contamination occurs;

sample is incorrectly labeled;

cryopreservation fails;

biological material is lost.

The tribunal would likely need scientific expert evidence.

Relevant evidence may include:

laboratory records;

temperature logs;

quality-control reports;

cryogenic monitoring records;

sample-identification records;

chain-of-custody documents.

The LifeCell dispute demonstrates the potentially serious consequences of losing biological material. (Indian Kanoon)

16. Chain of Custody

A stem-cell agreement should specify responsibility at every stage:

Birth/collection

↓

Packaging

↓

Transportation

↓

Laboratory receipt

↓

Testing

↓

Processing

↓

Cryopreservation

↓

Long-term storage

↓

Retrieval

↓

Clinical application

This is particularly important because the biological material may be irreplaceable.

17. Medical Negligence and Arbitration

A patient may allege:

improper administration;

inadequate monitoring;

negligent handling;

contamination;

failure to diagnose complications;

inappropriate treatment;

inadequate disclosure of risks.

The arbitration agreement does not automatically eliminate medical-regulatory obligations.

The tribunal should distinguish:

Contractual question

"Did the provider perform the promised service?"

from

Regulatory/medical question

"Was the treatment legally and professionally permissible?"

The first may be arbitrable; the second may require consideration of mandatory law and public regulatory authority.

18. Intellectual Property Disputes

Stem-cell technology can involve valuable IP concerning:

cell-processing techniques;

differentiation techniques;

culture media;

cryopreservation technology;

genetic modification;

diagnostic platforms;

therapeutic formulations;

manufacturing processes.

Contracts should identify whether arbitration covers:

ownership;

licensing;

royalties;

confidentiality;

misuse of technology;

research results.

Westenfelder demonstrates why the precise contractual relationship and scope of the arbitration clause matter in biotechnology disputes. (MidPage)

19. Clinical Trial Disputes

Stem-cell clinical trials may involve:

sponsor;

investigator;

hospital;

research organization;

biotechnology company;

patient participants.

Potential disputes include:

failure to recruit participants;

failure to follow protocol;

delayed payments;

protocol deviations;

adverse-event reporting;

data ownership;

publication rights;

regulatory approval.

Commercial disputes between the sponsor and research institution can ordinarily be drafted for arbitration, while statutory protections owed directly to human subjects cannot simply be contracted away.

20. Cross-Border Stem Cell Arbitration

Cross-border disputes are particularly complicated.

For example:

Indian biotechnology company

vs.

Chinese cell-therapy company

could involve:

Indian regulatory law;

Chinese regulatory law;

foreign exchange law;

intellectual-property law;

clinical-trial rules;

data-transfer rules;

confidentiality obligations;

tax;

export/import restrictions.

The CASI–Juventas proceedings illustrate the practical existence of international arbitration in the cell-therapy/biotechnology sector. (Jus Mundi)

21. Seat of Arbitration

The contract should specify the seat.

For example:

"The seat of arbitration shall be New Delhi, India."

The seat generally determines the supervisory court and the procedural arbitration law.

This is different from:

physical hearing location;

governing law;

jurisdiction clause.

For international stem-cell agreements, ambiguity over seat can create expensive preliminary litigation.

22. Governing Law

A stem-cell agreement should separately identify:

governing substantive law;

seat of arbitration;

institutional rules;

language;

number of arbitrators.

Example:

Indian substantive law + Singapore seat + SIAC arbitration.

This provides greater predictability for international biotechnology transactions.

23. Expert Evidence

Stem-cell disputes are unusually dependent on expert evidence.

Experts may be required in:

hematology;

regenerative medicine;

cell biology;

molecular biology;

genetics;

cryopreservation;

oncology;

clinical pharmacology;

laboratory accreditation.

The tribunal should preferably establish an expert timetable at an early stage.

24. Confidentiality and Patient Data

Stem-cell disputes can contain highly sensitive information:

DNA profiles;

genetic information;

medical history;

family relationships;

disease information;

clinical-trial records.

The arbitration clause should therefore be supported by a comprehensive confidentiality regime.

The agreement should specify:

who can access medical records;

whether experts can receive samples;

anonymization requirements;

cybersecurity requirements;

permitted disclosure to regulators;

retention/deletion periods.

25. Interim Measures

Urgent relief can be crucial.

For example, one party may fear that a biotechnology partner will:

destroy cell samples;

transfer biological material;

disclose research;

misuse patents;

sell proprietary technology;

terminate storage arrangements;

move samples to another jurisdiction.

The arbitration agreement should permit appropriate interim relief through the tribunal and, where legally available, courts.

Tenet Healthcare v. Maharaj is useful because the contractual arrangements expressly contemplated judicial relief for irreparable harm notwithstanding the arbitration mechanism. (FindLaw)

26. Damages in Stem Cell Arbitration

Possible damages include:

Contract damages

For failure to provide agreed services.

Consequential damages

Where legally recoverable and sufficiently foreseeable.

Refund

For services not performed.

Replacement costs

Where replacement biological material is contractually possible.

Research losses

In biotechnology collaboration disputes.

Lost commercial opportunity

Potentially relevant in commercial contracts, subject to proof and applicable law.

Non-economic damages

Their availability depends heavily on the governing law and nature of the claim.

The irreplaceability of biological material makes conventional damages analysis particularly difficult.

27. Liability Limitation Clauses

Stem-cell companies frequently seek clauses such as:

"The company's liability shall not exceed the fees paid by the customer."

Such clauses should be carefully drafted.

A tribunal may examine whether the limitation is legally effective in relation to:

gross negligence;

fraud;

willful misconduct;

statutory violations;

personal injury;

death;

destruction of biological material.

A liability cap should therefore expressly state the claims to which it applies and any statutory exceptions.

28. Consumer Contracts and Unfair Arbitration Clauses

Stem-cell banking agreements may be standard-form consumer contracts.

Cohen v. CBR Systems is particularly useful because the court considered challenges to the arbitration provision, including arguments concerning the adhesive nature of the contract and the presentation of the arbitration clause. The court nevertheless compelled arbitration. (Justia Law)

Therefore, businesses should make arbitration provisions:

conspicuous;

understandable;

accessible;

consistent with applicable consumer law.

29. Model Arbitration Clause

A sophisticated stem-cell therapy agreement could use language along these lines:

"Any dispute, controversy or claim arising out of or relating to this Agreement, including its formation, validity, interpretation, performance, breach, termination, preservation, processing, transportation, storage, retrieval or use of biological material, shall be finally resolved by arbitration in accordance with the agreed institutional arbitration rules. The seat of arbitration shall be [place]. The language of arbitration shall be English. The tribunal shall consist of three arbitrators unless the parties agree otherwise. Nothing in this clause shall prevent a competent court or regulatory authority from exercising powers that cannot lawfully be excluded by agreement, including powers concerning mandatory healthcare, public-health, criminal or regulatory matters."

That final qualification is particularly important for stem-cell agreements.

30. Recommended Contractual Clauses

A comprehensive stem-cell contract should contain separate provisions dealing with:

Nature of treatment

Experimental status

Informed consent

Regulatory approvals

Clinical-trial status

Collection procedure

Sample identification

Chain of custody

Transportation

Cryopreservation

Storage standards

Viability testing

Retrieval

Replacement material

Adverse events

Insurance

Patient confidentiality

Genetic data

Intellectual property

Research results

Publication rights

Payment

Refund

Liability

Force majeure

Regulatory change

Termination

Emergency relief

Arbitration

Governing law and seat

31. Comparative Table of Key Cases

The first six provide particularly useful arbitration/biotechnology authorities; the Indian cases are important for understanding the mandatory regulatory and medical-law boundaries within which a stem-cell arbitration must operate. (FindLaw)

32. Key Legal Principles

The principal lessons are:

1. Arbitration depends on a valid agreement

A biotechnology dispute does not become arbitrable merely because it is commercial.

2. Scope matters

Westenfelder demonstrates that an arbitration clause may not extend to every dispute between parties involved in a stem-cell project. (MidPage)

3. Biological material requires special contractual protection

The LifeCell and CBR cases demonstrate the importance of collection, transportation, preservation and storage obligations. (Indian Kanoon)

4. Mandatory regulation cannot simply be contracted away

Yash Charitable Trust is especially important on this point. (Indian Kanoon)

5. Informed consent is fundamental

A patient's signature does not necessarily validate an otherwise unlawful or inadequately disclosed medical procedure.

6. Expert evidence is essential

Scientific questions should ordinarily be supported by qualified medical and laboratory experts.

7. International cell-therapy disputes can be arbitrated

The CASI–Juventas proceedings demonstrate the use of institutional international arbitration in the biotechnology/cell-therapy sector. (Jus Mundi)

8. Consumer arbitration clauses must be carefully drafted

Cohen v. CBR Systems illustrates judicial scrutiny of arbitration clauses in standard-form stem-cell banking contracts. (Justia Law)

Conclusion

Stem cell therapy arbitration is a specialized form of healthcare and biotechnology arbitration in which contractual autonomy operates alongside mandatory medical, pharmaceutical, consumer-protection and public-health regulation.

The most significant reported authorities include Tenet Healthcare Corp. v. Maharaj, Cohen v. CBR Systems, Polesuk v. CBR Systems, Westenfelder v. Novo Ventures, Cesca Therapeutics v. SynGen, and CASI Pharmaceuticals v. Juventas Cell Therapy, supplemented by important Indian authorities such as Yash Charitable Trust v. Union of India and the LifeCell disputes. (FindLaw)

For an Indian stem-cell agreement, the safest drafting approach is therefore to distinguish commercial disputes that can be arbitrated from mandatory regulatory, criminal, professional-disciplinary and other non-arbitrable matters, while expressly addressing biological-sample custody, informed consent, regulatory approvals, expert evidence, confidentiality, data protection, interim measures, liability and cross-border enforcement.